BioSpace News Archive

Linaclotide abstract recognized as a Presidential Poster Recipient

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced they will be presenting new scientific data at the American College of Rheumatology’s (ACR/ARHP) Annual Meeting being held November 9-12, 2019 in Atlanta, GA.

CarePredict, the leading AI-powered preventive senior care platform announced today the launch of the third generation of their smart wearable - CarePredict Tempo™ Series 3.

HiFiBiO Therapeutics, a pioneer in innovative biotherapeutics with a unique single-cell analytics platform for extensive immune profiling, today announced the formation of a Scientific Advisory Board (SAB) comprised of experts in immunology, oncology and cell therapy, as well as drug discovery and development.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will participate in Solebury Trout’s KOL Event for analysts and investors on November 15, 2019 at 11am ET in New York City at the offices of White & Case, LLP.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the AMA has issued a Proprietary Laboratory Analyses (PLA) Common Procedural Terminology (CPT®) Code for the DermTech Pigmented Lesion Assay.

Kyocera Corporation (President: Hideo Tanimoto) announced that its smart, portable carbohydrate monitoring system was named the Grand Prix Runner-Up in the Smart X category at the 2019 CEATEC Awards.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, including feasibility and safety data, at 50% of total patient enrollment

Funding led by ATW Partners and SJF Ventures with follow-on Investment from Health Catalyst Capital, RTI International, and Inova Health Systems

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s third quarter 2019 financial results will be released after market close on Monday, November 4, 2019.